# Appendix A

## Diversity amongst anti-hapten antibodies

This appendix outlines some of the studies that have been performed to determine the extent of variation between different antibody molecules raised against a common, simple determinant. Four different examples are provided, in which four different haptens were used as the immunogen. Copies of the respective academic publications are provided herewith.

These and other studies demonstrate that widely diverse sequences are generated during the immune response to any particular antigen, due to a combination of V, D, and J region selection, VJ and VDJ splicing, and somatic mutation.

The operation of these events make it essentially impossible to identically reproduce an antibody with a somatically mutated sequence by immunizing a second animal. Clones producing antibody molecules with identical sequences have been described only: a) when based on a nearly *un-mutated germ-line sequence*, in which case the antibody is observable during the primary response; or b) when obtained from the *same* animal, in which case the responsible antibody-producing cells are derived from the same clonal progenitor.

### Example 1:

Nahmias et al. (1988, J. Immunol. 140:1304) raised a panel of 14 monoclonal antibodies against the  $\beta$ -adrenergic hapten alprenolol, also using the same mouse strain. The 14 antibodies utilized at least seven  $V_L$ , four  $J_L$ , eight  $V_H$ , and three  $J_H$  genes (Table I), and also demonstrated extensive splicing and mutational diversity (Figures 3-5). Only three pairs of hybridomas used the same H and L chain gene rearrangements; each related pair was obtained from a single mouse and was apparently derived from the same clone (page 1308,  $\P$  3).

#### Example 2:

Stenzel-Poore et al. (1989, J. Immunol. 143:4123) raised a panel of monoclonal antibodies against phosphocholine (PC) in BALB/c mice and F1 hybrids. Fourteen monoclonal antibodies were selected from the high affinity Group II anti-PC that emerge in the secondary

response. The 14 antibodies utilized four  $V_L$ , six  $J_L$ , six to eleven  $V_H$ , four  $J_H$  genes, and more than five D genes (Table III). The antibodies each had an average of 3.6 replacement mutations in the heavy chain and 3.1 replacement mutations in the light chain (Table V). Here, as in other studies, the mutations were found *throughout the variable region* — they were enriched in the complementarity determining region (CDR), but also occurred in the framework (Table V).

### Example 3:

Blier et al. (1987, J. Immunol. 139:3996) obtained monoclonal antibodies specific for 4-hydroxy-3-nitrophenyl acetate (NP). Twenty eight hybridomas were obtained during the secondary response in the *same mouse*. Fourteen were derived from different clones. Amongst the 14 families, about 3 different V<sub>H</sub>, 3 different D and 3 different J<sub>H</sub> were used (Table I). Nine families used the same V<sub>H</sub> and D region genes, but were all spliced differently to create differences in the CDR4 region (Figure 1). Amongst the 28 antibody panel, there was an average of 8.1 amino acid replacements in each heavy chain variable region (Table III). On average, 2.5 replacements had occurred after divergence of members of each clone family (Table III). This indicates that somatic mutation is an ongoing process within B-cell clones during the immune response.

# Example 4:

Leahy et al. (1988, Proc. Natl. Acad. Sci. USA 85:3661) raised a panel of 12 monoclonal antibodies against a DNP spin-label hapten. The mouse strain used was BALB/c, the same as was used in the disclosure of the instant application to develop 1A7. The amino acid sequences of both the heavy and light chains of the Leahy panel demonstrate that different clones are derived from different germ-line V genes, exhibit junctional diversity around the splice sites, and show mutational divergence from common germ-line precursor sequences. As a result, the sequences are dramatically different amongst the antibodies. These sequences are reproduced below:

	-15 !	-5 !	l	10	20	30 35 36
ANOZ				60801 AKU4		GYSITSDYAVN VI
ANO1	.KSY.	LINELATES				
EONA			• • • • •	• • • • • • •	· · · L · · · · S · ·	
ANOZ			• • • • •	D		
ANOS	ME.HV.F.F.	CUTA VU				G.S.H
ANOS	ME.HV.F.F.	SVIA.VH.	17 . P . U	AE . A C	A.VKMS.KAS	TFYVMH .V
ANO4	MGVSV.F.F.	SCTA WICE		AE . A 9	A.VKMS.KAS	
ANOS	MGWSY.I.F.	LAGIA.VHU	Ku	E	A.VKIS.KAS	
AN11	MCV F F	CCTA VI		F - AE G	A.VK.S.KAS A.VKMS.KAS	
AN12	MEUNIAN E	LSGIA.VH.		E K . G	A.VKMS.KAS	TFYVMH .V
ANOS	MEWNWVV.F.I MEWLWNF.I	LSCIA. VYAL	JG . M . U	A E	A.VK.S.KIS	.FTFR.S.IG .L
ANIO	MNECES IE	TALAUS.UAC	11		E IVE IS . KAS	TF.TAGIO .V
7/110	MNFGFS.IF.	VLVLK.VUCI	K . V .		G.LK.S.AAS	.FTFS.YAMS .V
	40	52 53	60		0 -	82 83 90
ANO2	POERCHYL CLAVO	ABC		<u>.</u>		ABC I
ANO1	ROFPGNKLEWMG	rm3 1363	IKTAP:	2FK2K1211	KUISKNOFFL	GLKSVTTEDTATYF
EDNA			MM	KN		KY
ANO7		. 1	MM	Km	• • • • • • • • • •	K.NY
ANOS	K.R QG I			K	1.1.111111	N
ANOS	K.R. QG I .		. v u	KIKUKAIL.	A.K.SSTAYM	S.L.SD.S.V.Y
ANO4	K.KQGI.V	1145 21.1	. E Q	KPKUKAIL.	A.K.SSTAYM	ş.L.şs.v.y
ANOS	RQGI.I	TIME CHE	INK E	KIKGKAIL.	ISSTVYI	S . L . S V
ANII	K.KQGI.		. N E	KPK.KAILN	V.K.SSTAYM	. IS.L.SS.V.Y
ANIZ	K.KQSIAV		. K E	KPKGKAIL.	S.K.SSTAYI	E.S.L.SS.V.Y
ANOS	QKMKG.K.I.V		UI	KPIGKAKL.	VSSTAYM	.FS.LS.I.Y
ANIO	T.ERRVAS		7 K . MEI	UVC FT 6	LE. ASTAY.	.ISNLRNDA .MS.LRSM.Y
		) Juli		. 4	NAK.ILY.	.M2.LK2M.Y
	95 100		105	110		
4403		DEFGHIJK	!	!		
ANO2 ANO1	CARGWP		WGOGT			
	EDDGYYI		s			
ANO3 ANO7	EGYGYF		• • • • • • • •			
ANO5	VIYYYGSSY\		• • • • • • • •			
ANO6	YYGSS		•••••]			
ANO4	HYGRS .V.YGYDG		• • • • • • •			
ANO9			1			
ANII	R.GSYVGG FGYYGR		N			
AN12	VD.INRG	YWYEDV				
ANOS	.G.TDYYGST					
ANIO	WGHRYDVL	YYAMD.				
7410	wenktovi	υ.		.15		

Fig. 1. Deduced amino acid sequences of the V regions of the heavy chains of the anti-DNP-SL monoclonal antibodies AN01-AN12.

	-20 1	-10 I	1	10	20	27 ABCDEF
ANOZ	MOFOVO	IFSFLLISASV	TI SECOTVI TO	TERA THEACOC	CVUTHTCC	***
ANOI		II J. CLIJAJI	M	SOLW THOMOLP	EKAIMIC2	H22
ANOS	• • • • • • • • • • • • • • • • • • • •	· · · · · · · · · · · · · · · · · · ·	• [7 · · · · · · · · ·			• • •
	• •		. <u></u>		• • • • • • • •	
ANO9	*****	<u></u> I	VMEN	· · · · · I · · · Ł .	S.R	
ANO5	MRCS	LOFLGVLMFVI	SGVS.DI	DELSNPVAS	.S.SIS.R	STKSLL
ANO6	MRCS	LOFLGVLMFWI	SGVS.DI	DELSNPVTS	.S. SIS R	STKSLL
ANO4	MR.L.	AELLG.LLFCF	LGV.CD.OMN.		DT1.1.H	
ANO8	MRF.	VQVLG.LLLVI	SGAQCDVQI	LISVIA		K
AN11	MVFT	POILG.MLFWI		TL.VT		• • •
AN12	MHHTSMGIKMES.	OV VEVELUI	SCAD U M	UPP 7 0	03.3L3.K.	
ANO7	MAL	.SLI.SLL.LS	SCATE A V	EC. 1	DK - 21 K	
ANIO	MAU	. 31 1 . 311 . 13	SGA15.A.V.,	FZ. FII	. T L RS	5.N
ANIO	MAW	.SLI.SLL.LS	SGA15.A.V.,	ES. LTT	.TLRS	S.T
	30			50 76	<b>o</b>	80
	_!	.1	1 1	1		i
ANOZ	ZVYYMYWYQQ	KPGSSPRLLIY	DTSNLASGVPV	'RFSGSGSGTS'	YSLTISRME	EAFDAA
ANOI	3 7	K KPW	L A	L	_	
ANO3	S F	R KPW . F	L	. •	•	
ANO9	N F	.SDAK.V	YP. A	. M		· · · · · ·
ANO5	TR DGRILLNIFL.	C O U	LM.TR SN		F F 1/1	
ANOS	* Y K   UG K   . L N . P L . J		IM TD CN			
ANO4	NINVVLS	NI K	YA UT C		v	
ANOR	SISK.LAE	YTNY	CC T O T C		1	P I.
AN11	CVCNNIUE	CUE V	36.1.01.3	· · · · · · DI	T St .	P. F.
AN12	SVSNNLH.F	. ShE K	YA.USII.S	· · · <u>·</u> · · · · . DI	T.S.NSV.	TFG
	DVSTAVA	U K	SA.YRYTD	· T DI	TFSVC	)L.
ANO7	GAVIISTATATA	UML F 1G G	G.N.R.P A	1100		· T C
ANIO	GAVT.SNSVK.V.E	DHLFTGG	GSN.R.PA	LI.DK/	A AGAC	IT.E.
	90 95	100	106 109			
	_ I ABC		A I			
ANO2	TYYCQQWSSYPP	ITFGVGTK	LEL KRA			
ANOI	N	S	1			
ANO3		A				
ANO9	FT.S.	SA			•	
ANO5	VLVEF.	L A				
ANOS	VLVEF.					
ANO4			•••			
		Ľ.L.G	]			
ANOB	MHNE	Yg	I			
ANII	M.F.,.SN.V.	F.,G	I			
AN12	VH.HY.S.	YG	1			
ANO7	I.F.AL.Y.NH	LVG	TVLGOP			
ANIO	V.F.AL.Y.NH	LVG.A.				

Fig. 2. Deduced amino acid sequences of the V regions of the light chains of the anti-DNP-SL monoclonal antibodies AN01-AN12.